HALIFAX, Nova Scotia, Nov. 12, 2018 /CNW/ -- Densitas, Inc., a breast imaging analytics innovator based in Halifax, Novia Scotia, today announced the signing of a new Alliance Partner Agreement with Blackford. This agreement gives Blackford the right to promote, market, sell, distribute, and license densitasdensity™ directly via integration with the Blackford Platform™. Work will now commence to integrate densitasdensity™ with the Blackford Platform.
"The platform approach will help us bring new products to market more quickly, support our scaling activities, and simplify integration for our customers" says Mohamed Abdolell, CEO of Densitas. "We expect the Blackford Platform to reduce our time to market and shorten our sales cycle as we will be incorporated as an extension of the Blackford Platform infrastructure."
The densitasdensity™ software provides an automated mechanism for quantifying and recording percent breast tissue density, and making it readily available to the radiologist. Beyond speeding and simplifying the process of quantifying breast density, densitasdensity™ standardizes the density measurement which enables uniform application of risk-based stratification of screen eligible women aimed at ensuring those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research.
Blackford CEO, Ben Panter said this of the alliance:
"We are delighted to add densitasdensity™ to the curated marketplace of applications available through Blackford Platform. We look forward to working with Densitas to provide our customers and channel partners multiple imaging applications that can be easily deployed and maintained."
densitasdensity™ will be demonstrated at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago. Densitas personnel will be available to discuss the benefits and capabilities of density in Booth #3274 – South Hall at RSNA and in the machine learning pavilion, Kiosk #7367W – North Hall.
To learn more about Blackford Platform applications including densitasdensity™, book a demo at RSNA or visit Blackford at Booth #7364.
Densitas' vision is to move the needle in breast cancer screening through tailored patient management for sustainable healthcare service delivery and improved outcomes. Densitas develops advanced breast imaging analytics technologies powered by machine learning with the goal to deliver on-demand actionable insights that improve the quality of breast health management. Our products tackle the key challenges facing women's imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health and in our virtual press kit.
Blackford provide a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK's leading business angel syndicates. For more information, visit www.blackfordanalysis.com
SOURCE Densitas, Inc.
For further information: Media Contact Densitas, Alex Morris, firstname.lastname@example.org, 647-470-4363; Media Contact Blackford, Greg Kingston, email@example.com, +44 131 6688 411